Pediatric Cancers | Topics

 
FDA Approved Azacitidine for Newly Diagnosed Juvenile Myelomonocytic Leukemia
May 20, 2022

Based on the results of the AZA-JMML-001 trial, the FDA has approved azacitidine for use in newly diagnosed juvenile myelomonocytic leukemia.

Omburtamab BLA Re-Submitted to FDA for Pediatric Neuroblastoma
April 04, 2022

A biologics license application for omburtamab was resubmitted following a refusal to file letter in 2020 for pediatric patients with central nervous system/leptomeningeal metastatic from neuroblastoma.

Addition of Sorafenib to Chemotherapy May Improve Outcomes in Pediatric HAR FLT3/ITD1+ AML
April 04, 2022

Pediatric patients with high allelic ratio FLT3/ITD–positive acute myeloid leukemia may benefit from treatment with sorafenib plus chemotherapy.

Addition of Bortezomib to Chemo Yields Benefit for Newly Diagnosed Pediatric T-ALL/T-LL
March 11, 2022

Pediatric patients with newly diagnosed pediatric T-cell lymphoblastic lymphoma experienced an improvement in survival following treatment with bortezomib and chemotherapy.

Validated Breast Cancer Risk Prediction Model Created for Survivors of Pediatric Cancer Treated With Chest Radiation
February 02, 2022

Breast cancer risk was estimated among survivors of pediatric cancer who were treated with chest radiation with a newly developed and validated breast cancer risk prediction model.

IMX-110 Granted Rare Pediatric Disease Designation by FDA for Rhabdomyosarcoma
January 05, 2022

IMX-110, which was granted a rare pediatric disease designation for patients with rhabdomyosarcoma, is currently being assessed as part of a phase 1b/2a study.

FDA Approves Rituximab Plus Chemo for Select Pediatric Hematologic Malignancies
December 03, 2021

The FDA has approved rituximab plus chemotherapy for previously untreated pediatric CD20-postive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, and mature B-cell acute leukemia following results from the phase 3 Inter-B-NHL Ritux 2010 study.

Opsoclonus-Myoclonus–Associated Neuroblastoma With Bone Marrow Metastases: What Would Be the Best Treatment Option?
October 22, 2021

In this clinical quandary, investigators determine how to best treat patients with opsoclonus-myoclonus–associated neuroblastoma with bone marrow metastases.

Vincristine/Irinotecan Plus Temozolomide Shows Improved Efficacy in Relapsed/Refractory Rhabdomyosarcoma
October 14, 2021

The addition of temozolomide to vincristine and irinotecan appears to be a new standard of care for adult and pediatric patients with relapsed/refractory rhabdomyosarcoma, according to the European Paediatric Soft Tissue Sarcoma Group.

FDA Grants Rare Pediatric Disease Designation to 177Lu-omburtamab-DTPA for Medulloblastoma
October 11, 2021

Pediatric patients with medulloblastoma may experience benefit from 177Lu-omburtamab-DTPA, which was granted a rare pediatric disease designation by the FDA.